2-(4'-bromo-2-fluoro-4-biphenylyl)propionic acid | 53592-06-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(4'-bromo-2-fluoro-4-biphenylyl)propionic acid
• 英文别名: 2-[4-(4-Bromophenyl)-3-fluorophenyl]propanoic acid
• CAS: 53592-06-6
• 化学式: C₁₅H₁₂BrFO₂
• 分子量: 323.161
• InChiKey: WYOFSNNMXVPITN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(4'-bromo-2-fluoro-4-biphenylyl)propionic acid 、 4-羟基苯硼酸 在 palladium diacetate 、 四丁基溴化铵 、 potassium carbonate 作用下， 反应 1.0h， 生成 2-(2"-fluoro-4-hydroxy-[1,1';4',1']terphenyl-4"-yl)propionic acid
  参考文献：
  名称：

  Synthesis and Biological Activity of Flurbiprofen Analogues as Selective Inhibitors of β-Amyloid_1-42 Secretion

  摘要：

  Flurbiprofen, a nonsteroidal antiinflammatory drug (NSAID), has been recently described to selectively inhibit beta-amyloid(1-42) (A beta 42) secretion, the most toxic component of the senile plaques present in the brain of Alzheimer patients. The use of this NSAID in Alzheimer's disease (AD) is hampered by a significant gastrointestinal toxicity associated with cyclooxygenase (COX) inhibition. New flurbiprofen analogues were synthesized, with the aim of increasing A beta 42 inhibitory potency while removing anti-COX activity. In vitro ADME developability parameters were taken into account in order to identify optimized compounds at an early stage of the project. Appropriate substitution patterns at the alpha position of flurbiprofen allowed for the complete removal of anti-COX activity, while modifications at the terminal phenyl ring resulted in increased inhibitory potency on A beta 42 secretion. In rats, some of the compounds appeared to be well absorbed after oral administration and to penetrate into the central nervous system. Studies in a transgenic mice model of AD showed that selected compounds significantly decreased plasma A beta 42 concentrations. These new flurbiprofen analogues represent potential drug candidates to be developed for the treatment of AD.

  DOI：

  10.1021/jm0502541
• 作为产物：
  描述：

  2-[(3-氟-4-硝基苯基)甲基]丙二酸二乙基酯 在 palladium on activated charcoal 盐酸 、 sodium hydroxide 、 四(三苯基膦)钯 、 氢气 、 sodium carbonate 、 sodium nitrite 作用下， 以 乙二醇二甲醚 、 乙醇 为溶剂， 反应 14.0h， 生成 2-(4'-bromo-2-fluoro-4-biphenylyl)propionic acid
  参考文献：
  名称：

  Synthesis and Biological Activity of Flurbiprofen Analogues as Selective Inhibitors of β-Amyloid_1-42 Secretion

  摘要：

  Flurbiprofen, a nonsteroidal antiinflammatory drug (NSAID), has been recently described to selectively inhibit beta-amyloid(1-42) (A beta 42) secretion, the most toxic component of the senile plaques present in the brain of Alzheimer patients. The use of this NSAID in Alzheimer's disease (AD) is hampered by a significant gastrointestinal toxicity associated with cyclooxygenase (COX) inhibition. New flurbiprofen analogues were synthesized, with the aim of increasing A beta 42 inhibitory potency while removing anti-COX activity. In vitro ADME developability parameters were taken into account in order to identify optimized compounds at an early stage of the project. Appropriate substitution patterns at the alpha position of flurbiprofen allowed for the complete removal of anti-COX activity, while modifications at the terminal phenyl ring resulted in increased inhibitory potency on A beta 42 secretion. In rats, some of the compounds appeared to be well absorbed after oral administration and to penetrate into the central nervous system. Studies in a transgenic mice model of AD showed that selected compounds significantly decreased plasma A beta 42 concentrations. These new flurbiprofen analogues represent potential drug candidates to be developed for the treatment of AD.

  DOI：

  10.1021/jm0502541

文献信息

• Aromatic halogenation using carborane catalyst
  作者：Chandrababu Naidu Kona、Rikuto Oku、Shotaro Nakamura、Masahiro Miura、Koji Hirano、Yuji Nishii

  DOI：10.1016/j.chempr.2023.10.006

  日期：2024.1

  transformations. Classical electrophilic aromatic halogenation using molecular halogens and Lewis/Brønsted acid activators is still a promising synthetic tool; however, it suffers from handling difficulties, low selectivity, and limited functional group tolerance. We herein introduce carborane-based Lewis base catalysts for aromatic halogenation using -halosuccinimides. The developed reaction system

  卤代芳烃一直是现代有机化学领域中的一类重要化学品，因为卤化物官能团提供了许多可能的转化。使用分子卤素和路易斯/布朗斯台德酸活化剂的经典亲电芳香族卤化仍然是一种有前途的合成工具；然而，它存在操作困难、选择性低和官能团耐受性有限的问题。我们在此介绍基于碳硼烷的路易斯碱催化剂，用于使用卤代琥珀酰亚胺进行芳族卤化。所开发的反应体系易于应用于药物分子的后期功能化和多卤代芳烃的高效合成。 β-碳硼烷支架最适合催化，并且通过装饰簇顶点进行可能的微调对于调节卤物种的电子性质以最大化催化性能非常重要。
• Synthesis and Biological Activity of Flurbiprofen Analogues as Selective Inhibitors of β-Amyloid₁_-₄₂ Secretion
  作者：Ilaria Peretto、Stefano Radaelli、Carlo Parini、Michele Zandi、Luca F. Raveglia、Giulio Dondio、Laura Fontanella、Paola Misiano、Chiara Bigogno、Andrea Rizzi、Benedetta Riccardi、Marcello Biscaioli、Silvia Marchetti、Paola Puccini、Silvia Catinella、Ivano Rondelli、Valentina Cenacchi、Pier Tonino Bolzoni、Paola Caruso、Gino Villetti、Fabrizio Facchinetti、Elda Del Giudice、Nadia Moretto、Bruno P. Imbimbo

  DOI：10.1021/jm0502541

  日期：2005.9.1

  Flurbiprofen, a nonsteroidal antiinflammatory drug (NSAID), has been recently described to selectively inhibit beta-amyloid(1-42) (A beta 42) secretion, the most toxic component of the senile plaques present in the brain of Alzheimer patients. The use of this NSAID in Alzheimer's disease (AD) is hampered by a significant gastrointestinal toxicity associated with cyclooxygenase (COX) inhibition. New flurbiprofen analogues were synthesized, with the aim of increasing A beta 42 inhibitory potency while removing anti-COX activity. In vitro ADME developability parameters were taken into account in order to identify optimized compounds at an early stage of the project. Appropriate substitution patterns at the alpha position of flurbiprofen allowed for the complete removal of anti-COX activity, while modifications at the terminal phenyl ring resulted in increased inhibitory potency on A beta 42 secretion. In rats, some of the compounds appeared to be well absorbed after oral administration and to penetrate into the central nervous system. Studies in a transgenic mice model of AD showed that selected compounds significantly decreased plasma A beta 42 concentrations. These new flurbiprofen analogues represent potential drug candidates to be developed for the treatment of AD.